Loading…
Reported covered position: LA, Sen. Mike Rounds; LA, Rep. Kristi Noem.
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
American Rescue Plan Act of 2021
Client: AMERICAN COLLEGE OF GASTROENTEROLOGY · Firm: ALSTON & BIRD LLP
COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; H.R. 266/P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund to provide further relief to physician practices; S. 464/H.R. 2163, the Safe Step Act; H.R. 1319/P.L. 117-2, American Rescue Plan Act of 2021-issues related to economic and regulatory relief for health care providers; issues related to coverage of products under drug formulary.
American Rescue Plan Act of 2021
Client: AMERICAN COLLEGE OF GASTROENTEROLOGY · Firm: ALSTON & BIRD LLP
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
TROUTMAN PEPPER STRATEGIES OBO CIVITAS NETWORKS FOR HEALTH (FKA SHIEC) via ALSTON & BIRD LLP
2021 · third_quarter · Q3
Issues pertaining to the use, regulation and development of Health Information Exchanges.
Issues pertaining to the use, regulation and development of Health Information Exchanges.
Source: Senate LDA
| MEDICA |
| 6 |
| 2020–2021 |
| EYECARE COALITION (INFORMAL COALITION) | 5 | 2020–2021 |
| LEADINGAGE, INC. | 5 | 2018–2019 |
| BROOKDALE SENIOR LIVING INC. | 4 | 2020 |
| CHESAPEAKE REGIONAL INFORMATION SYSTEM FOR OUR PATIENTS (CRISP) | 4 | 2021 |
| ALABAMA HOSPITAL ASSOCIATION | 3 | 2021 |
| AMERICAN ORTHOTIC & PROSTHETIC ASSOCIATION (AOPA) | 3 | 2021 |
| GREATER NEW YORK HOSPITAL ASSOCIATION | 3 | 2018–2019 |
| PREMIER, INC. | 3 | 2018–2019 |
| TROUTMAN PEPPER STRATEGIES OBO CIVITAS NETWORKS FOR HEALTH (FKA SHIEC) | 3 | 2021 |
| HOLOGIC, INC. | 2 | 2021 |
| LEWIS & CLARK RURAL WATER SYSTEM | 2 | 2021 |
| ROSE ACRE FARMS, INC. | 2 | 2018 |
| AMERICAN COLLEGE OF OSTEOPATHIC FAMILY PHYSICIANS | 1 | 2021 |
| CHE SENIOR PSYCHOLOGICAL SERVICES | 1 | 2020 |
| FAIRVIEW HEALTH SERVICES | 1 | 2021 |
COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; H.R. 266/P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund to provide further relief to physician practices; S. 464/H.R. 2163, the Safe Step Act; H.R. 1319/P.L. 117-2, American Rescue Plan Act of 2021-issues related to economic and regulatory relief for health care providers.
American Rescue Plan Act of 2021
Client: AMERICAN COLLEGE OF GASTROENTEROLOGY · Firm: ALSTON & BIRD LLP
COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; H.R. 266/P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund to provide further relief to physician practices; S. 464/H.R. 2163, the Safe Step Act; H.R. 1319/P.L. 117-2, American Rescue Plan Act of 2021-issues related to economic and regulatory relief for health care providers.
To prevent across-the-board direct spending cuts, and for other purposes.
Client: AMERICAN COLLEGE OF GASTROENTEROLOGY · Firm: ALSTON & BIRD LLP
The Patient Protection and Affordable Care Act, Pub. L. 111-148, Section 4104; Colon cancer screening policies in Medicare; Medicare physician quality incentives; Advancement of physician quality registries as they relate to Medicare physician payment reform; Transparency in valuation of medical procedures under Medicare; Issues related to the Medicare physician fee schedule and payment policies for GI services; Proposed changes to Stark Law on self-referral and anti-kickback statute; Public Law 114-10 - The Medicare Access and CHIP Reauthorization Act of 2015 - implementation of payment model and reporting requirements, impact on physicians and QCDRs; physician burden reduction under Medicare, in general; H.R. 1868/P.L. 117-7, To prevent across-the-board direct spending cuts, and for other purposes/Medicare sequester.
To prevent across-the-board direct spending cuts, and for other purposes.
Client: AMERICAN COLLEGE OF GASTROENTEROLOGY · Firm: ALSTON & BIRD LLP
The Patient Protection and Affordable Care Act, Pub. L. 111-148, Section 4104; Colon cancer screening policies in Medicare; Medicare physician quality incentives; Advancement of physician quality registries as they relate to Medicare physician payment reform; Transparency in valuation of medical procedures under Medicare; Issues related to the Medicare physician fee schedule and payment policies for GI services; Proposed changes to Stark Law on self-referral and anti-kickback statute; Public Law 114-10 - The Medicare Access and CHIP Reauthorization Act of 2015 - implementation of payment model and reporting requirements, impact on physicians and QCDRs; physician burden reduction under Medicare, in general; H.R. 1868/P.L. 117-7, To prevent across-the-board direct spending cuts, and for other purposes/Medicare sequester; Policies to waive cost of certain diagnostic colorectal cancer procedures under Medicare; Policies to continue coverage and payment for telehealth services under Medicare.
To prevent across-the-board direct spending cuts, and for other purposes.
Client: AMERICAN COLLEGE OF GASTROENTEROLOGY · Firm: ALSTON & BIRD LLP
The Patient Protection and Affordable Care Act, Pub. L. 111-148, Section 4104; Colon cancer screening policies in Medicare; Medicare physician quality incentives; Advancement of physician quality registries as they relate to Medicare physician payment reform; Transparency in valuation of medical procedures under Medicare; Issues related to the Medicare physician fee schedule and payment policies for GI services; Proposed changes to Stark Law on self-referral and anti-kickback statute; Public Law 114-10 - The Medicare Access and CHIP Reauthorization Act of 2015 - implementation of payment model and reporting requirements, impact on physicians and QCDRs; physician burden reduction under Medicare, in general; H.R. 1868/P.L. 117-7, To prevent across-the-board direct spending cuts, and for other purposes/Medicare sequester; Policies to waive cost of certain diagnostic colorectal cancer procedures under Medicare; Policies to continue coverage and payment for telehealth services under Medicare.
Medicare Orthotics and Prosthetics Patient-Centered Care Act
Client: AMERICAN ORTHOTIC & PROSTHETIC ASSOCIATION (AOPA) · Firm: ALSTON & BIRD LLP
H.R. 1990, The Medicare Orthotics and Prosthetics Patient-Centered Care Act.
Medicare Orthotics and Prosthetics Patient-Centered Care Act
Client: AMERICAN ORTHOTIC & PROSTHETIC ASSOCIATION (AOPA) · Firm: ALSTON & BIRD LLP
H.R. 1990, The Medicare Orthotics and Prosthetics Patient-Centered Care Act.
Medicare Orthotics and Prosthetics Patient-Centered Care Act
Client: AMERICAN ORTHOTIC & PROSTHETIC ASSOCIATION (AOPA) · Firm: ALSTON & BIRD LLP
Issues related to S.2556/H.R. 1990, The Medicare Orthotics and Prosthetics Patient-Centered Care Act.
COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; H.R. 266/P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund to provide further relief to physician practices; S. 464/H.R. 2163, the Safe Step Act; H.R. 1319/P.L. 117-2, American Rescue Plan Act of 2021-issues related to economic and regulatory relief for health care providers.
COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; H.R. 266/P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund to provide further relief to physician practices; S. 464/H.R. 2163, the Safe Step Act; H.R. 1319/P.L. 117-2, American Rescue Plan Act of 2021-issues related to economic and regulatory relief for health care providers; issues related to coverage of products under drug formulary.
COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; H.R. 266/P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund to provide further relief to physician practices; S. 464/H.R. 2163, the Safe Step Act; H.R. 1319/P.L. 117-2, American Rescue Plan Act of 2021-issues related to economic and regulatory relief for health care providers.
Medicare Orthotics and Prosthetics Patient-Centered Care Act
Client: AMERICAN ORTHOTIC & PROSTHETIC ASSOCIATION (AOPA) · Firm: ALSTON & BIRD LLP
Issues related to S.2556/H.R. 1990, The Medicare Orthotics and Prosthetics Patient-Centered Care Act.
COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; H.R. 266/P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund to provide further relief to physician practices; S. 464/H.R. 2163, the Safe Step Act; H.R. 1319/P.L. 117-2, American Rescue Plan Act of 2021-issues related to economic and regulatory relief for health care providers.
COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; H.R. 266/P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund to provide further relief to physician practices; S. 464/H.R. 2163, the Safe Step Act; H.R. 1319/P.L. 117-2, American Rescue Plan Act of 2021-issues related to economic and regulatory relief for health care providers; issues related to coverage of products under drug formulary.
COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; H.R. 266/P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund to provide further relief to physician practices; S. 464/H.R. 2163, the Safe Step Act; H.R. 1319/P.L. 117-2, American Rescue Plan Act of 2021-issues related to economic and regulatory relief for health care providers.
Paycheck Protection Program and Health Care Enhancement Act
Client: AMERICAN COLLEGE OF GASTROENTEROLOGY · Firm: ALSTON & BIRD LLP
COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; H.R. 266/P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund to provide further relief to physician practices; S. 464/H.R. 2163, the Safe Step Act; H.R. 1319/P.L. 117-2, American Rescue Plan Act of 2021-issues related to economic and regulatory relief for health care providers.
Paycheck Protection Program and Health Care Enhancement Act
Client: AMERICAN COLLEGE OF GASTROENTEROLOGY · Firm: ALSTON & BIRD LLP
COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; H.R. 266/P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund to provide further relief to physician practices; S. 464/H.R. 2163, the Safe Step Act; H.R. 1319/P.L. 117-2, American Rescue Plan Act of 2021-issues related to economic and regulatory relief for health care providers; issues related to coverage of products under drug formulary.
Paycheck Protection Program and Health Care Enhancement Act
Client: AMERICAN COLLEGE OF GASTROENTEROLOGY · Firm: ALSTON & BIRD LLP
COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; H.R. 266/P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund to provide further relief to physician practices; S. 464/H.R. 2163, the Safe Step Act; H.R. 1319/P.L. 117-2, American Rescue Plan Act of 2021-issues related to economic and regulatory relief for health care providers.
Medicare Negotiation and Competitive Licensing Act of 2019
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R. 1046, Medicare Price Negotiation and Competitive Licensing Act; FY 2021 Medicare and Medicaid proposals, including proposed International Pricing Index; H.R. 7078, Evaluating Disparities and Outcomes of Telehealth During the COVID-19 Emergency Act of 2020; H.R. 7663, Protecting Access to Post-Covid-19 Telehealth Act of 2020; other telehealth issues; telehealth provisions in H.R. 133, Consolidated Appropriations Act of 2021.
Medicare Negotiation and Competitive Licensing Act of 2019
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R. 1046, Medicare Price Negotiation and Competitive Licensing Act; FY 2020 Medicare and Medicaid proposals, including proposed International Pricing Index; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; H.R. 19, Lower Costs, More Cures Act of 2019; S. 2543, Prescription Drug Pricing Reduction Act of 2019; issues concerning diagnosis, treatment, patient care for rare kidney disease; H.R. 7078, Evaluating Disparities and Outcomes of Telehealth During the COVID-19 Emergency Act of 2020 or the EDOT Act of 2020.
Medicare Negotiation and Competitive Licensing Act of 2019
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R. 1046, Medicare Price Negotiation and Competitive Licensing Act; FY 2020 Medicare and Medicaid proposals, including proposed International Pricing Index; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; H.R. 19, Lower Costs, More Cures Act of 2019; S. 2543, Prescription Drug Pricing Reduction Act of 2019; issues concerning diagnosis, treatment, patient care for rare kidney disease.
Medicare Negotiation and Competitive Licensing Act of 2019
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R. 1046, Medicare Price Negotiation and Competitive Licensing Act; FY 2020 Medicare and Medicaid proposals, including proposed International Pricing Index; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; H.R. 19, Lower Costs, More Cures Act of 2019; S. 2543, Prescription Drug Pricing Reduction Act of 2019; issues concerning diagnosis, treatment, patient care for rare kidney disease; H.R. 7078, Evaluating Disparities and Outcomes of Telehealth During the COVID-19 Emergency Act of 2020 or the EDOT Act of 2020; support of telehealth policies for rare disease patients.
To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Client: NOVO NORDISK INC. · Firm: ALSTON & BIRD LLP
H.R. 1530/S. 595 Treat and Reduce Obesity Act; Medicare Diabetes Prevention Program; Issues related to Medicare Part D; Issues related to International Pricing Index (IPI)/reference pricing in Medicare; H.R. 107 - related to maximum Medicaid rebates; Medicare Part D Rebate Rule; H.R.3 Lower Drug Costs Now Act of 2019; H.R. 19, Lower Costs, More Cures Act of 2019; S. 2543, Prescription Drug Pricing Reduction Act of 2019; H.R. 4906/S. 2199, Insulin Price Reduction Act.
H.R. 1046, Medicare Price Negotiation and Competitive Licensing Act; FY 2021 Medicare and Medicaid proposals, including proposed International Pricing Index; H.R. 7078, Evaluating Disparities and Outcomes of Telehealth During the COVID-19 Emergency Act of 2020; H.R. 7663, Protecting Access to Post-Covid-19 Telehealth Act of 2020; other telehealth issues; telehealth provisions in H.R. 133, Consolidated Appropriations Act of 2021.
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act; Newborn Screening legislation in general; Newborn Screening Saves Lives Reauthorization Act of 2019, H.R. 2507; Lower Health Care Costs Act, S. 1895; H.R. 4144, Ending the Diagnostic Odyssey Act of 2019; H.R. 534, Aidan's Law (newborn screening for ALD); H.R. 5062, Advancing Access to Precision Medicine Act; Kidney disease diagnosis, prevention, and care; H.R. 4712, Fairness in Orphan Drug Exclusivity Act; Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues concerning rare disease patients; Executive Order regarding Advancing American Kidney Health; issues concerning diagnosis, treatment, patient care for rare kidney disease; support of telehealth policies for rare disease patients; H.R. 133, Consolidated Appropriations Act of 2021.
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
Further Extension of Continuing Appropriations Act, 2021
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
Further Extension of Continuing Appropriations Act, 2021
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
Further Extension of Continuing Appropriations Act, 2021
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
Further Extension of Continuing Appropriations Act, 2021
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
H.R. 1530/S. 595 Treat and Reduce Obesity Act; Medicare Diabetes Prevention Program; Issues related to Medicare Part D; Issues related to International Pricing Index (IPI)/reference pricing in Medicare; H.R. 107 - related to maximum Medicaid rebates; Medicare Part D Rebate Rule; H.R.3 Lower Drug Costs Now Act of 2019; H.R. 19, Lower Costs, More Cures Act of 2019; S. 2543, Prescription Drug Pricing Reduction Act of 2019; H.R. 4906/S. 2199, Insulin Price Reduction Act.
Removing Barriers to Colorectal Cancer Screening Act of 2020
Client: AMERICAN COLLEGE OF GASTROENTEROLOGY · Firm: ALSTON & BIRD LLP
The Patient Protection and Affordable Care Act, Pub. L. 111-148, Section 4104; Colon cancer screening policies in Medicare; Medicare physician quality incentives; Advancement of physician quality registries as they relate to Medicare physician payment reform; Transparency in valuation of medical procedures under Medicare; Issues related to the Medicare physician fee schedule and payment policies for GI services; Proposed changes to Stark Law on self-referral and anti-kickback statute; Public Law 114-10 - The Medicare Access and CHIP Reauthorization Act of 2015 - implementation of payment model and reporting requirements, impact on physicians and QCDRs; physician burden reduction under Medicare, in general; Pub. Law 115-123, Section 51003, regarding technical amendments to Pub. Law 114-10; H.R. 1570/S. 668, The Removing Barriers to Colorectal Cancer Screening Act of 2019; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; issues regarding telehealth expansion.
Removing Barriers to Colorectal Cancer Screening Act of 2020
Client: AMERICAN COLLEGE OF GASTROENTEROLOGY · Firm: ALSTON & BIRD LLP
The Patient Protection and Affordable Care Act, Pub. L. 111-148, Section 4104; Colon cancer screening policies in Medicare; Medicare physician quality incentives; Advancement of physician quality registries as they relate to Medicare physician payment reform; Transparency in valuation of medical procedures under Medicare; Issues related to the Medicare physician fee schedule and payment policies for GI services; Proposed changes to Stark Law on self-referral and anti-kickback statute; Public Law 114-10 - The Medicare Access and CHIP Reauthorization Act of 2015 - implementation of payment model and reporting requirements, impact on physicians and QCDRs; physician burden reduction under Medicare, in general; Pub. Law 115-123, Section 51003, regarding technical amendments to Pub. Law 114-10; H.R. 1570/S. 668, The Removing Barriers to Colorectal Cancer Screening Act of 2019; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; issues regarding telehealth expansion.
Removing Barriers to Colorectal Cancer Screening Act of 2020
Client: AMERICAN COLLEGE OF GASTROENTEROLOGY · Firm: ALSTON & BIRD LLP
The Patient Protection and Affordable Care Act, Pub. L. 111-148, Section 4104; Colon cancer screening policies in Medicare; Medicare physician quality incentives; Advancement of physician quality registries as they relate to Medicare physician payment reform; Transparency in valuation of medical procedures under Medicare; Issues related to the Medicare physician fee schedule and payment policies for GI services; Proposed changes to Stark Law on self-referral and anti-kickback statute; Public Law 114-10 - The Medicare Access and CHIP Reauthorization Act of 2015 - implementation of payment model and reporting requirements, impact on physicians and QCDRs; physician burden reduction under Medicare, in general; Pub. Law 115-123, Section 51003, regarding technical amendments to Pub. Law 114-10; H.R. 1570/S. 668, The Removing Barriers to Colorectal Cancer Screening Act of 2019; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; issues regarding telehealth expansion; issues regarding proposed reductions to Medicare physician services; the Consolidated Appropriations Act of 2021, Division CC, Title I, Sections 113 (regarding Medicare physician payment changes) and 122 (regarding coverage of colon cancer screening).
Removing Barriers to Colorectal Cancer Screening Act of 2020
Client: AMERICAN COLLEGE OF GASTROENTEROLOGY · Firm: ALSTON & BIRD LLP
The Patient Protection and Affordable Care Act, Pub. L. 111-148, Section 4104; Colon cancer screening policies in Medicare; Medicare physician quality incentives; Advancement of physician quality registries as they relate to Medicare physician payment reform; Transparency in valuation of medical procedures under Medicare; Issues related to the Medicare physician fee schedule and payment policies for GI services; Proposed changes to Stark Law on self-referral and anti-kickback statute; Public Law 114-10 - The Medicare Access and CHIP Reauthorization Act of 2015 - implementation of payment model and reporting requirements, impact on physicians and QCDRs; physician burden reduction under Medicare, in general; Pub. Law 115-123, Section 51003, regarding technical amendments to Pub. Law 114-10; H.R. 1570/S. 668, The Removing Barriers to Colorectal Cancer Screening Act of 2019; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; issues regarding telehealth expansion; issues regarding proposed reductions to Medicare physician services.
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
H.R. 1530/S. 595 Treat and Reduce Obesity Act; Medicare Diabetes Prevention Program; Issues related to Medicare Part D; Issues related to International Pricing Index (IPI)/reference pricing in Medicare; H.R. 107 - related to maximum Medicaid rebates; Medicare Part D Rebate Rule; H.R.3 Lower Drug Costs Now Act of 2019; H.R. 19, Lower Costs, More Cures Act of 2019; S. 2543, Prescription Drug Pricing Reduction Act of 2019; H.R. 4906/S. 2199, Insulin Price Reduction Act.
H.R. 1046, Medicare Price Negotiation and Competitive Licensing Act; FY 2020 Medicare and Medicaid proposals, including proposed International Pricing Index; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; H.R. 19, Lower Costs, More Cures Act of 2019; S. 2543, Prescription Drug Pricing Reduction Act of 2019; issues concerning diagnosis, treatment, patient care for rare kidney disease; H.R. 7078, Evaluating Disparities and Outcomes of Telehealth During the COVID-19 Emergency Act of 2020 or the EDOT Act of 2020.
H.R. 1046, Medicare Price Negotiation and Competitive Licensing Act; FY 2020 Medicare and Medicaid proposals, including proposed International Pricing Index; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; H.R. 19, Lower Costs, More Cures Act of 2019; S. 2543, Prescription Drug Pricing Reduction Act of 2019; issues concerning diagnosis, treatment, patient care for rare kidney disease.
H.R. 1046, Medicare Price Negotiation and Competitive Licensing Act; FY 2020 Medicare and Medicaid proposals, including proposed International Pricing Index; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; H.R. 19, Lower Costs, More Cures Act of 2019; S. 2543, Prescription Drug Pricing Reduction Act of 2019; issues concerning diagnosis, treatment, patient care for rare kidney disease; H.R. 7078, Evaluating Disparities and Outcomes of Telehealth During the COVID-19 Emergency Act of 2020 or the EDOT Act of 2020; support of telehealth policies for rare disease patients.
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
The Safe Step Act, H.R. 2279; Surprise Billing Legislation, in general; Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1531; Protecting People From Surprise Medical Bills Act, H.R. 3502; No Surprises Act, H.R. 3630; Lower Health Care Costs Act, S.1895; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; H.R. 266/P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund to provide further relief to physician practices.
The Safe Step Act, H.R. 2279; Surprise Billing Legislation, in general; Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1531; Protecting People From Surprise Medical Bills Act, H.R. 3502; No Surprises Act, H.R. 3630; Lower Health Care Costs Act, S.1895; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; H.R. 266/P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund to provide further relief to physician practices.
The Safe Step Act, H.R. 2279; Surprise Billing Legislation, in general; Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1531; Protecting People From Surprise Medical Bills Act, H.R. 3502; No Surprises Act, H.R. 3630; Lower Health Care Costs Act, S.1895; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers.
The Safe Step Act, H.R. 2279; Surprise Billing Legislation, in general; Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1531; Protecting People From Surprise Medical Bills Act, H.R. 3502; No Surprises Act, H.R. 3630; Lower Health Care Costs Act, S.1895; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; H.R. 266/P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund to provide further relief to physician practices.
More Efficient Tools to Realize Information for Consumers Act
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
More Efficient Tools to Realize Information for Consumers Act
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
More Efficient Tools to Realize Information for Consumers Act
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
More Efficient Tools to Realize Information for Consumers Act
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
Newborn Screening Saves Lives Reauthorization Act of 2019
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act; Newborn Screening legislation in general; Newborn Screening Saves Lives Reauthorization Act of 2019, H.R. 2507; Lower Health Care Costs Act, S. 1895; H.R. 4144, Ending the Diagnostic Odyssey Act of 2019; H.R. 534, Aidan's Law (newborn screening for ALD); H.R. 5062, Advancing Access to Precision Medicine Act; Kidney disease diagnosis, prevention, and care; H.R. 4712, Fairness in Orphan Drug Exclusivity Act; Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues concerning rare disease patients; Executive Order regarding Advancing American Kidney Health; issues concerning diagnosis, treatment, patient care for rare kidney disease; support of telehealth policies for rare disease patients; H.R. 133, Consolidated Appropriations Act of 2021.
Newborn Screening Saves Lives Reauthorization Act of 2019
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act; Newborn Screening legislation in general; Newborn Screening Saves Lives Reauthorization Act of 2019, H.R. 2507; Lower Health Care Costs Act, S. 1895; H.R. 4144, Ending the Diagnostic Odyssey Act of 2019; H.R. 534, Aidan's Law (newborn screening for ALD); H.R. 5062, Advancing Access to Precision Medicine Act; Kidney disease diagnosis, prevention, and care; H.R. 4712, Fairness in Orphan Drug Exclusivity Act; Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues concerning rare disease patients; Executive Order regarding Advancing American Kidney Health; issues concerning diagnosis, treatment, patient care for rare kidney disease; support of telehealth policies for rare disease patients.
Newborn Screening Saves Lives Reauthorization Act of 2019
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act; Newborn Screening legislation in general; Newborn Screening Saves Lives Reauthorization Act of 2019, H.R. 2507; Lower Health Care Costs Act, S. 1895; H.R. 4144, Ending the Diagnostic Odyssey Act of 2019; H.R. 534, Aidan's Law (newborn screening for ALD); H.R. 5062, Advancing Access to Precision Medicine Act; Kidney disease diagnosis, prevention, and care; H.R. 4712, Fairness in Orphan Drug Exclusivity Act; Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues concerning rare disease patients; Executive Order regarding Advancing American Kidney Health; issues concerning diagnosis, treatment, patient care, for rare kidney disease.
Newborn Screening Saves Lives Reauthorization Act of 2019
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act; Newborn Screening legislation in general; Newborn Screening Saves Lives Reauthorization Act of 2019, H.R. 2507; Lower Health Care Costs Act, S. 1895; H.R. 4144, Ending the Diagnostic Odyssey Act of 2019; H.R. 534, Aidan's Law (newborn screening for ALD); H.R. 5062, Advancing Access to Precision Medicine Act; Kidney disease diagnosis, prevention, and care; H.R. 4712, Fairness in Orphan Drug Exclusivity Act; Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues concerning rare disease patients; Executive Order regarding Advancing American Kidney Health; issues concerning diagnosis, treatment, patient care, for rare kidney disease.
To amend the Congressional Budget Act of 1974 respecting the scoring of preventive health savings.
Client: NOVO NORDISK INC. · Firm: ALSTON & BIRD LLP
Issues related to the scoring of Preventive Health Savings Act, H.R. 2584/S. 1361.
Paycheck Protection Program and Health Care Enhancement Act
Client: AMERICAN COLLEGE OF GASTROENTEROLOGY · Firm: ALSTON & BIRD LLP
The Safe Step Act, H.R. 2279; Surprise Billing Legislation, in general; Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1531; Protecting People From Surprise Medical Bills Act, H.R. 3502; No Surprises Act, H.R. 3630; Lower Health Care Costs Act, S.1895; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; H.R. 266/P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund to provide further relief to physician practices.
Paycheck Protection Program and Health Care Enhancement Act
Client: AMERICAN COLLEGE OF GASTROENTEROLOGY · Firm: ALSTON & BIRD LLP
The Safe Step Act, H.R. 2279; Surprise Billing Legislation, in general; Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1531; Protecting People From Surprise Medical Bills Act, H.R. 3502; No Surprises Act, H.R. 3630; Lower Health Care Costs Act, S.1895; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; H.R. 266/P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund to provide further relief to physician practices.
Paycheck Protection Program and Health Care Enhancement Act
Client: AMERICAN COLLEGE OF GASTROENTEROLOGY · Firm: ALSTON & BIRD LLP
The Safe Step Act, H.R. 2279; Surprise Billing Legislation, in general; Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1531; Protecting People From Surprise Medical Bills Act, H.R. 3502; No Surprises Act, H.R. 3630; Lower Health Care Costs Act, S.1895; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; H.R. 266/P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund to provide further relief to physician practices.
Issues related to the Orphan Drug Tax Credit; H.R. 2730/S. 1443, Credit for Caring Act of 2019; Coronavirus Aid, Relief, and Economic Security (CARES) Act and provisions regarding net operating loss (NOL).
Elijah E. Cummings Lower Drug Costs Now Act
Client: AMERICAN COLLEGE OF GASTROENTEROLOGY · Firm: ALSTON & BIRD LLP
The Patient Protection and Affordable Care Act, Pub. L. 111-148, Section 4104; Colon cancer screening policies in Medicare; Medicare physician quality incentives; Advancement of physician quality registries as they relate to Medicare physician payment reform; Transparency in valuation of medical procedures under Medicare; Issues related to the Medicare physician fee schedule and payment policies for GI services; Proposed changes to Stark Law on self-referral and anti-kickback statute; Public Law 114-10 - The Medicare Access and CHIP Reauthorization Act of 2015 - implementation of payment model and reporting requirements, impact on physicians and QCDRs; physician burden reduction under Medicare, in general; Pub. Law 115-123, Section 51003, regarding technical amendments to Pub. Law 114-10; H.R. 1570/S. 668, The Removing Barriers to Colorectal Cancer Screening Act of 2019; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; issues regarding telehealth expansion.
Elijah E. Cummings Lower Drug Costs Now Act
Client: NOVO NORDISK INC. · Firm: ALSTON & BIRD LLP
H.R. 1530/S. 595 Treat and Reduce Obesity Act; Medicare Diabetes Prevention Program; Issues related to Medicare Part D; Issues related to International Pricing Index (IPI)/reference pricing in Medicare; H.R. 107 - related to maximum Medicaid rebates; Medicare Part D Rebate Rule; H.R.3 Lower Drug Costs Now Act of 2019; H.R. 19, Lower Costs, More Cures Act of 2019; S. 2543, Prescription Drug Pricing Reduction Act of 2019; H.R. 4906/S. 2199, Insulin Price Reduction Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R. 1046, Medicare Price Negotiation and Competitive Licensing Act; FY 2020 Medicare and Medicaid proposals, including proposed International Pricing Index; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; H.R. 19, Lower Costs, More Cures Act of 2019; S. 2543, Prescription Drug Pricing Reduction Act of 2019; issues concerning diagnosis, treatment, patient care for rare kidney disease; H.R. 7078, Evaluating Disparities and Outcomes of Telehealth During the COVID-19 Emergency Act of 2020 or the EDOT Act of 2020.
Elijah E. Cummings Lower Drug Costs Now Act
Client: AMERICAN COLLEGE OF GASTROENTEROLOGY · Firm: ALSTON & BIRD LLP
The Patient Protection and Affordable Care Act, Pub. L. 111-148, Section 4104; Colon cancer screening policies in Medicare; Medicare physician quality incentives; Advancement of physician quality registries as they relate to Medicare physician payment reform; Transparency in valuation of medical procedures under Medicare; Issues related to the Medicare physician fee schedule and payment policies for GI services; Proposed changes to Stark Law on self-referral and anti-kickback statute; Public Law 114-10 - The Medicare Access and CHIP Reauthorization Act of 2015 - implementation of payment model and reporting requirements, impact on physicians and QCDRs; physician burden reduction under Medicare, in general; Pub. Law 115-123, Section 51003, regarding technical amendments to Pub. Law 114-10; H.R. 1570/S. 668, The Removing Barriers to Colorectal Cancer Screening Act of 2019; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; issues regarding telehealth expansion; issues regarding proposed reductions to Medicare physician services; the Consolidated Appropriations Act of 2021, Division CC, Title I, Sections 113 (regarding Medicare physician payment changes) and 122 (regarding coverage of colon cancer screening).
Elijah E. Cummings Lower Drug Costs Now Act
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R. 1046, Medicare Price Negotiation and Competitive Licensing Act; FY 2020 Medicare and Medicaid proposals, including proposed International Pricing Index; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; H.R. 19, Lower Costs, More Cures Act of 2019; S. 2543, Prescription Drug Pricing Reduction Act of 2019; issues concerning diagnosis, treatment, patient care for rare kidney disease.
Elijah E. Cummings Lower Drug Costs Now Act
Client: AMERICAN COLLEGE OF GASTROENTEROLOGY · Firm: ALSTON & BIRD LLP
The Patient Protection and Affordable Care Act, Pub. L. 111-148, Section 4104; Colon cancer screening policies in Medicare; Medicare physician quality incentives; Advancement of physician quality registries as they relate to Medicare physician payment reform; Transparency in valuation of medical procedures under Medicare; Issues related to the Medicare physician fee schedule and payment policies for GI services; Proposed changes to Stark Law on self-referral and anti-kickback statute; Public Law 114-10 - The Medicare Access and CHIP Reauthorization Act of 2015 - implementation of payment model and reporting requirements, impact on physicians and QCDRs; physician burden reduction under Medicare, in general; Pub. Law 115-123, Section 51003, regarding technical amendments to Pub. Law 114-10; H.R. 1570/S. 668, The Removing Barriers to Colorectal Cancer Screening Act of 2019; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; issues regarding telehealth expansion; issues regarding proposed reductions to Medicare physician services.
Elijah E. Cummings Lower Drug Costs Now Act
Client: AMERICAN COLLEGE OF GASTROENTEROLOGY · Firm: ALSTON & BIRD LLP
The Patient Protection and Affordable Care Act, Pub. L. 111-148, Section 4104; Colon cancer screening policies in Medicare; Medicare physician quality incentives; Advancement of physician quality registries as they relate to Medicare physician payment reform; Transparency in valuation of medical procedures under Medicare; Issues related to the Medicare physician fee schedule and payment policies for GI services; Proposed changes to Stark Law on self-referral and anti-kickback statute; Public Law 114-10 - The Medicare Access and CHIP Reauthorization Act of 2015 - implementation of payment model and reporting requirements, impact on physicians and QCDRs; physician burden reduction under Medicare, in general; Pub. Law 115-123, Section 51003, regarding technical amendments to Pub. Law 114-10; H.R. 1570/S. 668, The Removing Barriers to Colorectal Cancer Screening Act of 2019; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; issues regarding telehealth expansion.
Elijah E. Cummings Lower Drug Costs Now Act
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R. 1046, Medicare Price Negotiation and Competitive Licensing Act; FY 2020 Medicare and Medicaid proposals, including proposed International Pricing Index; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; H.R. 19, Lower Costs, More Cures Act of 2019; S. 2543, Prescription Drug Pricing Reduction Act of 2019; issues concerning diagnosis, treatment, patient care for rare kidney disease; H.R. 7078, Evaluating Disparities and Outcomes of Telehealth During the COVID-19 Emergency Act of 2020 or the EDOT Act of 2020; support of telehealth policies for rare disease patients.
Protecting People From Surprise Medical Bills Act
Client: AMERICAN COLLEGE OF GASTROENTEROLOGY · Firm: ALSTON & BIRD LLP
The Safe Step Act, H.R. 2279; Surprise Billing Legislation, in general; Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1531; Protecting People From Surprise Medical Bills Act, H.R. 3502; No Surprises Act, H.R. 3630; Lower Health Care Costs Act, S.1895; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; H.R. 266/P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund to provide further relief to physician practices.
Protecting People From Surprise Medical Bills Act
Client: AMERICAN COLLEGE OF GASTROENTEROLOGY · Firm: ALSTON & BIRD LLP
The Safe Step Act, H.R. 2279; Surprise Billing Legislation, in general; Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1531; Protecting People From Surprise Medical Bills Act, H.R. 3502; No Surprises Act, H.R. 3630; Lower Health Care Costs Act, S.1895; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers.
Protecting People From Surprise Medical Bills Act
Client: AMERICAN COLLEGE OF GASTROENTEROLOGY · Firm: ALSTON & BIRD LLP
The Safe Step Act, H.R. 2279; Surprise Billing Legislation, in general; Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1531; Protecting People From Surprise Medical Bills Act, H.R. 3502; No Surprises Act, H.R. 3630; Lower Health Care Costs Act, S.1895; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; H.R. 266/P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund to provide further relief to physician practices.
Protecting People From Surprise Medical Bills Act
Client: AMERICAN COLLEGE OF GASTROENTEROLOGY · Firm: ALSTON & BIRD LLP
The Safe Step Act, H.R. 2279; Surprise Billing Legislation, in general; Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1531; Protecting People From Surprise Medical Bills Act, H.R. 3502; No Surprises Act, H.R. 3630; Lower Health Care Costs Act, S.1895; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; H.R. 266/P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund to provide further relief to physician practices.
The Safe Step Act, H.R. 2279; Surprise Billing Legislation, in general; Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1531; Protecting People From Surprise Medical Bills Act, H.R. 3502; No Surprises Act, H.R. 3630; Lower Health Care Costs Act, S.1895; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; H.R. 266/P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund to provide further relief to physician practices.
The Safe Step Act, H.R. 2279; Surprise Billing Legislation, in general; Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1531; Protecting People From Surprise Medical Bills Act, H.R. 3502; No Surprises Act, H.R. 3630; Lower Health Care Costs Act, S.1895; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; H.R. 266/P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund to provide further relief to physician practices.
The Safe Step Act, H.R. 2279; Surprise Billing Legislation, in general; Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1531; Protecting People From Surprise Medical Bills Act, H.R. 3502; No Surprises Act, H.R. 3630; Lower Health Care Costs Act, S.1895; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; H.R. 266/P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund to provide further relief to physician practices.
The Safe Step Act, H.R. 2279; Surprise Billing Legislation, in general; Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1531; Protecting People From Surprise Medical Bills Act, H.R. 3502; No Surprises Act, H.R. 3630; Lower Health Care Costs Act, S.1895; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers.
General diabetes prevention; medication affordability and access; S. 1948/H.R. 3709, Chronic Disease Management Act; issues related to high deductible health plan pre-deductible coverage of treatments and services for chronic diseases; Medication affordability and access.
Ending the Diagnostic Odyssey Act of 2019
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act; Newborn Screening legislation in general; Newborn Screening Saves Lives Reauthorization Act of 2019, H.R. 2507; Lower Health Care Costs Act, S. 1895; H.R. 4144, Ending the Diagnostic Odyssey Act of 2019; H.R. 534, Aidan's Law (newborn screening for ALD); H.R. 5062, Advancing Access to Precision Medicine Act; Kidney disease diagnosis, prevention, and care; H.R. 4712, Fairness in Orphan Drug Exclusivity Act; Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues concerning rare disease patients; Executive Order regarding Advancing American Kidney Health; issues concerning diagnosis, treatment, patient care, for rare kidney disease.
Ending the Diagnostic Odyssey Act of 2019
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act; Newborn Screening legislation in general; Newborn Screening Saves Lives Reauthorization Act of 2019, H.R. 2507; Lower Health Care Costs Act, S. 1895; H.R. 4144, Ending the Diagnostic Odyssey Act of 2019; H.R. 534, Aidan's Law (newborn screening for ALD); H.R. 5062, Advancing Access to Precision Medicine Act; Kidney disease diagnosis, prevention, and care; H.R. 4712, Fairness in Orphan Drug Exclusivity Act; Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues concerning rare disease patients; Executive Order regarding Advancing American Kidney Health; issues concerning diagnosis, treatment, patient care for rare kidney disease; support of telehealth policies for rare disease patients; H.R. 133, Consolidated Appropriations Act of 2021.
Ending the Diagnostic Odyssey Act of 2019
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act; Newborn Screening legislation in general; Newborn Screening Saves Lives Reauthorization Act of 2019, H.R. 2507; Lower Health Care Costs Act, S. 1895; H.R. 4144, Ending the Diagnostic Odyssey Act of 2019; H.R. 534, Aidan's Law (newborn screening for ALD); H.R. 5062, Advancing Access to Precision Medicine Act; Kidney disease diagnosis, prevention, and care; H.R. 4712, Fairness in Orphan Drug Exclusivity Act; Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues concerning rare disease patients; Executive Order regarding Advancing American Kidney Health; issues concerning diagnosis, treatment, patient care for rare kidney disease; support of telehealth policies for rare disease patients.
Ending the Diagnostic Odyssey Act of 2019
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act; Newborn Screening legislation in general; Newborn Screening Saves Lives Reauthorization Act of 2019, H.R. 2507; Lower Health Care Costs Act, S. 1895; H.R. 4144, Ending the Diagnostic Odyssey Act of 2019; H.R. 534, Aidan's Law (newborn screening for ALD); H.R. 5062, Advancing Access to Precision Medicine Act; Kidney disease diagnosis, prevention, and care; H.R. 4712, Fairness in Orphan Drug Exclusivity Act; Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues concerning rare disease patients; Executive Order regarding Advancing American Kidney Health; issues concerning diagnosis, treatment, patient care, for rare kidney disease.
Fairness in Orphan Drug Exclusivity Act
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
Fairness in Orphan Drug Exclusivity Act
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act; Newborn Screening legislation in general; Newborn Screening Saves Lives Reauthorization Act of 2019, H.R. 2507; Lower Health Care Costs Act, S. 1895; H.R. 4144, Ending the Diagnostic Odyssey Act of 2019; H.R. 534, Aidan's Law (newborn screening for ALD); H.R. 5062, Advancing Access to Precision Medicine Act; Kidney disease diagnosis, prevention, and care; H.R. 4712, Fairness in Orphan Drug Exclusivity Act; Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues concerning rare disease patients; Executive Order regarding Advancing American Kidney Health; issues concerning diagnosis, treatment, patient care, for rare kidney disease.
Fairness in Orphan Drug Exclusivity Act
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act; Newborn Screening legislation in general; Newborn Screening Saves Lives Reauthorization Act of 2019, H.R. 2507; Lower Health Care Costs Act, S. 1895; H.R. 4144, Ending the Diagnostic Odyssey Act of 2019; H.R. 534, Aidan's Law (newborn screening for ALD); H.R. 5062, Advancing Access to Precision Medicine Act; Kidney disease diagnosis, prevention, and care; H.R. 4712, Fairness in Orphan Drug Exclusivity Act; Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues concerning rare disease patients; Executive Order regarding Advancing American Kidney Health; issues concerning diagnosis, treatment, patient care for rare kidney disease; support of telehealth policies for rare disease patients; H.R. 133, Consolidated Appropriations Act of 2021.
Fairness in Orphan Drug Exclusivity Act
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act; Newborn Screening legislation in general; Newborn Screening Saves Lives Reauthorization Act of 2019, H.R. 2507; Lower Health Care Costs Act, S. 1895; H.R. 4144, Ending the Diagnostic Odyssey Act of 2019; H.R. 534, Aidan's Law (newborn screening for ALD); H.R. 5062, Advancing Access to Precision Medicine Act; Kidney disease diagnosis, prevention, and care; H.R. 4712, Fairness in Orphan Drug Exclusivity Act; Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues concerning rare disease patients; Executive Order regarding Advancing American Kidney Health; issues concerning diagnosis, treatment, patient care for rare kidney disease; support of telehealth policies for rare disease patients.
Fairness in Orphan Drug Exclusivity Act
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
Fairness in Orphan Drug Exclusivity Act
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
Fairness in Orphan Drug Exclusivity Act
Client: TRAVERE THERAPEUTICS · Firm: ALSTON & BIRD LLP
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
Issues pertaining to the use, regulation and development of Health Information Exchanges.
Issues pertaining to the use, regulation and development of Health Information Exchanges.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2021 · third_quarter · Q3
Affordable Care Act Health Reform; Implementation of Health Reform; Medicare/Medicaid Reimbursement; Legislation for CMS; Medicare Cost Plan and Reimbursement; issues relating to the impact of the COVID-19 emergency.
Affordable Care Act Health Reform; Implementation of Health Reform; Medicare/Medicaid Reimbursement; Legislation for CMS; Medicare Cost Plan and Reimbursement; issues relating to the impact of the COVID-19 emergency.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MARYLAND+COALITION via ALSTON & BIRD LLP
2021 · third_quarter · Q3
Issues related to Medicare Advantage benchmarking and the Maryland All-Payer Demonstration.
Issues related to Medicare Advantage benchmarking and the Maryland All-Payer Demonstration.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LEWIS & CLARK RURAL WATER SYSTEM via ALSTON & BIRD LLP
2021 · third_quarter · Q3
Issues involving funding for water infrastructure.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHESAPEAKE REGIONAL INFORMATION SYSTEM FOR OUR PATIENTS (CRISP) via ALSTON & BIRD LLP
2021 · second_quarter · Q2
Issues related to improving public health data.
Filing targets: Health & Human Services, Dept of (HHS)
CHESAPEAKE REGIONAL INFORMATION SYSTEM FOR OUR PATIENTS (CRISP) via ALSTON & BIRD LLP
2021 · first_quarter · Q1
Issues related to improving public health data.
Filing targets: Health & Human Services, Dept of (HHS)
FAIRVIEW HEALTH SERVICES via ALSTON & BIRD LLP
2021 · third_quarter · Q3
Federal health program issues affecting hospitals. Affordable Care Act implementation issues.
Regulatory matters impacting hospitals.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
DEXCOM, INC. via ALSTON & BIRD LLP
2021 · third_quarter · Q3
Issues related to coverage and reimbursement for continuous glucose monitor; issues relating to the impact of the COVID-19 emergency.
Issues related to coverage and reimbursement for continuous glucose monitor; issues relating to the impact of the COVID-19 emergency.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CHESAPEAKE REGIONAL INFORMATION SYSTEM FOR OUR PATIENTS (CRISP) via ALSTON & BIRD LLP
2021 · third_quarter · Q3
Issues related to improving public health data.
Filing targets: Health & Human Services, Dept of (HHS)
AMERICAN ORTHOTIC & PROSTHETIC ASSOCIATION (AOPA) via ALSTON & BIRD LLP
2021 · third_quarter · Q3
Issues related to S.2556/H.R. 1990, The Medicare Orthotics and Prosthetics Patient-Centered Care Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN COLLEGE OF OSTEOPATHIC FAMILY PHYSICIANS via ALSTON & BIRD LLP
2021 · third_quarter · Q3
Medicare, Medicaid and general health care issues.
Medicare, Medicaid and general health care issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN COLLEGE OF GASTROENTEROLOGY via ALSTON & BIRD LLP
2021 · third_quarter · Q3
COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; H.R. 266/P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund to provide further relief to physician practices; S. 464/H.R. 2163, the Safe Step Act; H.R. 1319/P.L. 117-2, American Rescue Plan Act of 2021-issues related to economic and regulatory relief for health care providers; issues related to coverage of products under drug formulary.
The Patient Protection and Affordable Care Act, Pub. L. 111-148, Section 4104; Colon cancer screening policies in Medicare; Medicare physician quality incentives; Advancement of physician quality registries as they relate to Medicare physician payment reform; Transparency in valuation of medical procedures under Medicare; Issues related to the Medicare physician fee schedule and payment policies for GI services; Proposed changes to Stark Law on self-referral and anti-kickback statute; Public Law 114-10 - The Medicare Access and CHIP Reauthorization Act of 2015 - implementation of payment model and reporting requirements, impact on physicians and QCDRs; physician burden reduction under Medicare, in general; H.R. 1868/P.L. 117-7, To prevent across-the-board direct spending cuts, and for other purposes/Medicare sequester; Policies to waive cost of certain diagnostic colorectal cancer procedures under Medicare; Policies to continue coverage and payment for telehealth services under Medicare.
ALABAMA HOSPITAL ASSOCIATION via ALSTON & BIRD LLP
2021 · third_quarter · Q3
General health care issues.
General health care issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHESAPEAKE REGIONAL INFORMATION SYSTEM FOR OUR PATIENTS (CRISP) via ALSTON & BIRD LLP
2021 · first_quarter · RR
Improving public health data.
MARYLAND+COALITION via ALSTON & BIRD LLP
2021 · second_quarter · Q2
Issues related to Medicare Advantage benchmarking and the Maryland All-Payer Demonstration.
Issues related to Medicare Advantage benchmarking and the Maryland All-Payer Demonstration.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TROUTMAN PEPPER STRATEGIES OBO CIVITAS NETWORKS FOR HEALTH (FKA SHIEC) via ALSTON & BIRD LLP
2021 · second_quarter · Q2
Issues pertaining to the use, regulation and development of Health Information Exchanges.
Issues pertaining to the use, regulation and development of Health Information Exchanges.
Issues pertaining to the use, regulation and development of Health Information Exchanges.
AMERICAN COLLEGE OF GASTROENTEROLOGY via ALSTON & BIRD LLP
2021 · second_quarter · Q2
The Patient Protection and Affordable Care Act, Pub. L. 111-148, Section 4104; Colon cancer screening policies in Medicare; Medicare physician quality incentives; Advancement of physician quality registries as they relate to Medicare physician payment reform; Transparency in valuation of medical procedures under Medicare; Issues related to the Medicare physician fee schedule and payment policies for GI services; Proposed changes to Stark Law on self-referral and anti-kickback statute; Public Law 114-10 - The Medicare Access and CHIP Reauthorization Act of 2015 - implementation of payment model and reporting requirements, impact on physicians and QCDRs; physician burden reduction under Medicare, in general; H.R. 1868/P.L. 117-7, To prevent across-the-board direct spending cuts, and for other purposes/Medicare sequester; Policies to waive cost of certain diagnostic colorectal cancer procedures under Medicare; Policies to continue coverage and payment for telehealth services under Medicare.
COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; H.R. 266/P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund to provide further relief to physician practices; S. 464/H.R. 2163, the Safe Step Act; H.R. 1319/P.L. 117-2, American Rescue Plan Act of 2021-issues related to economic and regulatory relief for health care providers.
2021 · second_quarter · Q2
Affordable Care Act Health Reform; Implementation of Health Reform; Medicare/Medicaid Reimbursement; Legislation for CMS; Medicare Cost Plan and Reimbursement; issues relating to the impact of the COVID-19 emergency.
Affordable Care Act Health Reform; Implementation of Health Reform; Medicare/Medicaid Reimbursement; Legislation for CMS; Medicare Cost Plan and Reimbursement; issues relating to the impact of the COVID-19 emergency.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
LEWIS & CLARK RURAL WATER SYSTEM via ALSTON & BIRD LLP
2021 · second_quarter · Q2
Issues involving funding for water infrastructure.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HOLOGIC, INC. via ALSTON & BIRD LLP
2021 · second_quarter · Q2
Issues related to women's health, including prevention, diagnostics and imaging; Issues related to breast and cervical health and issues related to COVID-19 diagnostic testing.
Issues related to women's health, including prevention, diagnostics and imaging; Issues related to breast and cervical health and issues related to COVID-19 diagnostic testing.
Issues related to women's health, including prevention, diagnostics and imaging; Issues related to breast and cervical health and issues related to COVID-19 diagnostic testing.
EYECARE COALITION (INFORMAL COALITION) via ALSTON & BIRD LLP
2021 · second_quarter · 2T
Issues related to the Federal Trade Commission Contact Lens Rule.
Issues related to the Federal Trade Commission Contact Lens Rule.
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
DEXCOM, INC. via ALSTON & BIRD LLP
2021 · second_quarter · Q2
Issues related to coverage and reimbursement for continuous glucose monitor; issues relating to the impact of the COVID-19 emergency.
Issues related to coverage and reimbursement for continuous glucose monitor; issues relating to the impact of the COVID-19 emergency.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERICAN ORTHOTIC & PROSTHETIC ASSOCIATION (AOPA) via ALSTON & BIRD LLP
2021 · second_quarter · Q2
H.R. 1990, The Medicare Orthotics and Prosthetics Patient-Centered Care Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALABAMA HOSPITAL ASSOCIATION via ALSTON & BIRD LLP
2021 · second_quarter · Q2
General health care issues.
General health care issues.
Filing targets: SENATE
TROUTMAN PEPPER STRATEGIES OBO CIVITAS NETWORKS FOR HEALTH (FKA SHIEC) via ALSTON & BIRD LLP
2021 · second_quarter · RR
Issues pertaining to the use, regulation and development of Health Information Exchanges
Issues pertaining to the use, regulation and development of Health Information Exchanges
Issues pertaining to the use, regulation and development of Health Information Exchanges
AMERICAN ORTHOTIC & PROSTHETIC ASSOCIATION (AOPA) via ALSTON & BIRD LLP
2021 · second_quarter · RA
H.R. 1990, The Medicare Orthotics and Prosthetics Patient-Centered Care Act.
AMERICAN COLLEGE OF GASTROENTEROLOGY via ALSTON & BIRD LLP
2021 · first_quarter · Q1
COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; H.R. 266/P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund to provide further relief to physician practices; S. 464/H.R. 2163, the Safe Step Act; H.R. 1319/P.L. 117-2, American Rescue Plan Act of 2021-issues related to economic and regulatory relief for health care providers.
The Patient Protection and Affordable Care Act, Pub. L. 111-148, Section 4104; Colon cancer screening policies in Medicare; Medicare physician quality incentives; Advancement of physician quality registries as they relate to Medicare physician payment reform; Transparency in valuation of medical procedures under Medicare; Issues related to the Medicare physician fee schedule and payment policies for GI services; Proposed changes to Stark Law on self-referral and anti-kickback statute; Public Law 114-10 - The Medicare Access and CHIP Reauthorization Act of 2015 - implementation of payment model and reporting requirements, impact on physicians and QCDRs; physician burden reduction under Medicare, in general; H.R. 1868/P.L. 117-7, To prevent across-the-board direct spending cuts, and for other purposes/Medicare sequester.
MARYLAND+COALITION via ALSTON & BIRD LLP
2021 · first_quarter · Q1
Issues related to Medicare Advantage benchmarking and the Maryland All-Payer Demonstration.
Issues related to Medicare Advantage benchmarking and the Maryland All-Payer Demonstration.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · first_quarter · Q1
Affordable Care Act Health Reform; Implementation of Health Reform; Medicare/Medicaid Reimbursement; Legislation for CMS; Medicare Cost Plan and Reimbursement; issues relating to the impact of the COVID-19 emergency.
Affordable Care Act Health Reform; Implementation of Health Reform; Medicare/Medicaid Reimbursement; Legislation for CMS; Medicare Cost Plan and Reimbursement; issues relating to the impact of the COVID-19 emergency.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
HOLOGIC, INC. via ALSTON & BIRD LLP
2021 · first_quarter · Q1
Issues related to women's health, including prevention, diagnostics and imaging; Issues related to breast and cervical health and issues related to COVID-19 diagnostic testing.
Issues related to women's health, including prevention, diagnostics and imaging; Issues related to breast and cervical health and issues related to COVID-19 diagnostic testing.
Issues related to women's health, including prevention, diagnostics and imaging; Issues related to breast and cervical health and issues related to COVID-19 diagnostic testing.
EYECARE COALITION (INFORMAL COALITION) via ALSTON & BIRD LLP
2021 · first_quarter · Q1
Issues related to the Federal Trade Commission Contact Lens Rule.
Issues related to the Federal Trade Commission Contact Lens Rule.
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
DEXCOM, INC. via ALSTON & BIRD LLP
2021 · first_quarter · Q1
Issues related to coverage and reimbursement for continuous glucose monitor; issues relating to the impact of the COVID-19 emergency.
Issues related to coverage and reimbursement for continuous glucose monitor; issues relating to the impact of the COVID-19 emergency.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALABAMA HOSPITAL ASSOCIATION via ALSTON & BIRD LLP
2021 · first_quarter · Q1
General health care issues.
General health care issues.
Filing targets: SENATE
TRAVERE THERAPEUTICS via ALSTON & BIRD LLP
2020 · fourth_quarter · Q4
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
H.R. 1046, Medicare Price Negotiation and Competitive Licensing Act; FY 2021 Medicare and Medicaid proposals, including proposed International Pricing Index; H.R. 7078, Evaluating Disparities and Outcomes of Telehealth During the COVID-19 Emergency Act of 2020; H.R. 7663, Protecting Access to Post-Covid-19 Telehealth Act of 2020; other telehealth issues; telehealth provisions in H.R. 133, Consolidated Appropriations Act of 2021.
AMERICAN COLLEGE OF GASTROENTEROLOGY via ALSTON & BIRD LLP
2020 · fourth_quarter · Q4
The Safe Step Act, H.R. 2279; Surprise Billing Legislation, in general; Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1531; Protecting People From Surprise Medical Bills Act, H.R. 3502; No Surprises Act, H.R. 3630; Lower Health Care Costs Act, S.1895; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; H.R. 266/P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund to provide further relief to physician practices.
The Patient Protection and Affordable Care Act, Pub. L. 111-148, Section 4104; Colon cancer screening policies in Medicare; Medicare physician quality incentives; Advancement of physician quality registries as they relate to Medicare physician payment reform; Transparency in valuation of medical procedures under Medicare; Issues related to the Medicare physician fee schedule and payment policies for GI services; Proposed changes to Stark Law on self-referral and anti-kickback statute; Public Law 114-10 - The Medicare Access and CHIP Reauthorization Act of 2015 - implementation of payment model and reporting requirements, impact on physicians and QCDRs; physician burden reduction under Medicare, in general; Pub. Law 115-123, Section 51003, regarding technical amendments to Pub. Law 114-10; H.R. 1570/S. 668, The Removing Barriers to Colorectal Cancer Screening Act of 2019; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; issues regarding telehealth expansion; issues regarding proposed reductions to Medicare physician services; the Consolidated Appropriations Act of 2021, Division CC, Title I, Sections 113 (regarding Medicare physician payment changes) and 122 (regarding coverage of colon cancer screening).
2020 · fourth_quarter · Q4
Affordable Care Act Health Reform; Implementation of Health Reform; Medicare/Medicaid Reimbursement; Legislation for CMS; Medicare Cost Plan and Reimbursement; issues relating to the impact of the COVID-19 emergency.
Affordable Care Act Health Reform; Implementation of Health Reform; Medicare/Medicaid Reimbursement; Legislation for CMS; Medicare Cost Plan and Reimbursement; issues relating to the impact of the COVID-19 emergency.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MARYLAND+COALITION via ALSTON & BIRD LLP
2020 · fourth_quarter · Q4
Issues related to Medicare Advantage benchmarking and the Maryland All-Payer Demonstration.
Issues related to Medicare Advantage benchmarking and the Maryland All-Payer Demonstration.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EYECARE COALITION (INFORMAL COALITION) via ALSTON & BIRD LLP
2020 · fourth_quarter · Q4
Issues related to the Federal Trade Commission Contact Lens Rule.
Issues related to the Federal Trade Commission Contact Lens Rule.
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
DEXCOM, INC. via ALSTON & BIRD LLP
2020 · fourth_quarter · Q4
Issues related to coverage and reimbursement for continuous glucose monitor; issues relating to the impact of the COVID-19 emergency.
Issues related to coverage and reimbursement for continuous glucose monitor; issues relating to the impact of the COVID-19 emergency.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BROOKDALE SENIOR LIVING, INC. via ALSTON & BIRD LLP
2020 · fourth_quarter · Q4
Reimbursement and regulatory issues related to assisted and independent living; COVID-19 related legislation.
Reimbursement and regulatory issues related to assisted and independent living; COVID-19 related legislation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TRAVERE THERAPEUTICS via ALSTON & BIRD LLP
2020 · third_quarter · Q3
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
H.R. 1046, Medicare Price Negotiation and Competitive Licensing Act; FY 2020 Medicare and Medicaid proposals, including proposed International Pricing Index; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; H.R. 19, Lower Costs, More Cures Act of 2019; S. 2543, Prescription Drug Pricing Reduction Act of 2019; issues concerning diagnosis, treatment, patient care for rare kidney disease; H.R. 7078, Evaluating Disparities and Outcomes of Telehealth During the COVID-19 Emergency Act of 2020 or the EDOT Act of 2020; support of telehealth policies for rare disease patients.
2020 · third_quarter · Q3
Affordable Care Act Health Reform; Implementation of Health Reform; Medicare/Medicaid Reimbursement; Legislation for CMS; Medicare Cost Plan and Reimbursement; issues relating to the impact of the COVID-19 emergency.
Affordable Care Act Health Reform; Implementation of Health Reform; Medicare/Medicaid Reimbursement; Legislation for CMS; Medicare Cost Plan and Reimbursement; issues relating to the impact of the COVID-19 emergency.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MARYLAND+COALITION via ALSTON & BIRD LLP
2020 · third_quarter · Q3
Issues related to Medicare Advantage benchmarking and the Maryland All-Payer Demonstration.
Issues related to Medicare Advantage benchmarking and the Maryland All-Payer Demonstration.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EYECARE COALITION (INFORMAL COALITION) via ALSTON & BIRD LLP
2020 · third_quarter · Q3
Issues related to the Federal Trade Commission Contact Lens Rule.
Issues related to the Federal Trade Commission Contact Lens Rule.
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
DEXCOM, INC. via ALSTON & BIRD LLP
2020 · third_quarter · Q3
Issues related to coverage and reimbursement for continuous glucose monitor; issues relating to the impact of the COVID-19 emergency.
Issues related to coverage and reimbursement for continuous glucose monitor; issues relating to the impact of the COVID-19 emergency.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BROOKDALE SENIOR LIVING, INC. via ALSTON & BIRD LLP
2020 · third_quarter · Q3
Reimbursement and regulatory issues related to assisted and independent living; COVID-19 related legislation.
Reimbursement and regulatory issues related to assisted and independent living; COVID-19 related legislation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERICAN COLLEGE OF GASTROENTEROLOGY via ALSTON & BIRD LLP
2020 · third_quarter · Q3
The Patient Protection and Affordable Care Act, Pub. L. 111-148, Section 4104; Colon cancer screening policies in Medicare; Medicare physician quality incentives; Advancement of physician quality registries as they relate to Medicare physician payment reform; Transparency in valuation of medical procedures under Medicare; Issues related to the Medicare physician fee schedule and payment policies for GI services; Proposed changes to Stark Law on self-referral and anti-kickback statute; Public Law 114-10 - The Medicare Access and CHIP Reauthorization Act of 2015 - implementation of payment model and reporting requirements, impact on physicians and QCDRs; physician burden reduction under Medicare, in general; Pub. Law 115-123, Section 51003, regarding technical amendments to Pub. Law 114-10; H.R. 1570/S. 668, The Removing Barriers to Colorectal Cancer Screening Act of 2019; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; issues regarding telehealth expansion; issues regarding proposed reductions to Medicare physician services.
EYECARE COALITION (INFORMAL COALITION) via ALSTON & BIRD LLP
2020 · third_quarter · RR
Issues related to the Federal Trade Commission (FTC) Contact Lens Rule.
Issues related to the Federal Trade Commission (FTC) Contact Lens Rule.
2020 · second_quarter · Q2
Affordable Care Act Health Reform; Implementation of Health Reform; Medicare/Medicaid Reimbursement; Legislation for CMS; Medicare Cost Plan and Reimbursement; issues relating to the impact of the COVID-19 emergency.
Affordable Care Act Health Reform; Implementation of Health Reform; Medicare/Medicaid Reimbursement; Legislation for CMS; Medicare Cost Plan and Reimbursement; issues relating to the impact of the COVID-19 emergency.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MARYLAND+COALITION via ALSTON & BIRD LLP
2020 · second_quarter · Q2
Issues related to Medicare Advantage benchmarking and the Maryland All-Payer Demonstration.
Issues related to Medicare Advantage benchmarking and the Maryland All-Payer Demonstration.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEXCOM, INC. via ALSTON & BIRD LLP
2020 · second_quarter · 2A
Issues related to coverage and reimbursement for continuous glucose monitor; issues relating to the impact of the COVID-19 emergency.
Issues related to coverage and reimbursement for continuous glucose monitor; issues relating to the impact of the COVID-19 emergency.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BROOKDALE SENIOR LIVING, INC. via ALSTON & BIRD LLP
2020 · second_quarter · Q2
Reimbursement and regulatory issues related to assisted and independent living; COVID-19 related legislation.
Reimbursement and regulatory issues related to assisted and independent living; COVID-19 related legislation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DEXCOM, INC. via ALSTON & BIRD LLP
2020 · second_quarter · Q2
Issues related to coverage and reimbursement for continuous glucose monitor.
Issues related to coverage and reimbursement for continuous glucose monitor.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CHE SENIOR PSYCHOLOGICAL SERVICES via ALSTON & BIRD LLP
2020 · second_quarter · Q2
Medicare Payment and coverage of behavioral health services, Medicare audit standards of these services.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TRAVERE THERAPEUTICS via ALSTON & BIRD LLP
2020 · second_quarter · Q2
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act; Newborn Screening legislation in general; Newborn Screening Saves Lives Reauthorization Act of 2019, H.R. 2507; Lower Health Care Costs Act, S. 1895; H.R. 4144, Ending the Diagnostic Odyssey Act of 2019; H.R. 534, Aidan's Law (newborn screening for ALD); H.R. 5062, Advancing Access to Precision Medicine Act; Kidney disease diagnosis, prevention, and care; H.R. 4712, Fairness in Orphan Drug Exclusivity Act; Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues concerning rare disease patients; Executive Order regarding Advancing American Kidney Health; issues concerning diagnosis, treatment, patient care, for rare kidney disease.
H.R. 1046, Medicare Price Negotiation and Competitive Licensing Act; FY 2020 Medicare and Medicaid proposals, including proposed International Pricing Index; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; H.R. 19, Lower Costs, More Cures Act of 2019; S. 2543, Prescription Drug Pricing Reduction Act of 2019; issues concerning diagnosis, treatment, patient care for rare kidney disease; H.R. 7078, Evaluating Disparities and Outcomes of Telehealth During the COVID-19 Emergency Act of 2020 or the EDOT Act of 2020.
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2020 · second_quarter · Q2
Issues related to FDA regulation of tobacco products.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN COLLEGE OF GASTROENTEROLOGY via ALSTON & BIRD LLP
2020 · second_quarter · Q2
The Safe Step Act, H.R. 2279; Surprise Billing Legislation, in general; Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1531; Protecting People From Surprise Medical Bills Act, H.R. 3502; No Surprises Act, H.R. 3630; Lower Health Care Costs Act, S.1895; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; H.R. 266/P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund to provide further relief to physician practices.
The Patient Protection and Affordable Care Act, Pub. L. 111-148, Section 4104; Colon cancer screening policies in Medicare; Medicare physician quality incentives; Advancement of physician quality registries as they relate to Medicare physician payment reform; Transparency in valuation of medical procedures under Medicare; Issues related to the Medicare physician fee schedule and payment policies for GI services; Proposed changes to Stark Law on self-referral and anti-kickback statute; Public Law 114-10 - The Medicare Access and CHIP Reauthorization Act of 2015 - implementation of payment model and reporting requirements, impact on physicians and QCDRs; physician burden reduction under Medicare, in general; Pub. Law 115-123, Section 51003, regarding technical amendments to Pub. Law 114-10; H.R. 1570/S. 668, The Removing Barriers to Colorectal Cancer Screening Act of 2019; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; issues regarding telehealth expansion.
BROOKDALE SENIOR LIVING, INC. via ALSTON & BIRD LLP
2020 · first_quarter · RR
Issues related to health care legislation; senior living services; implementation of CARES Act.
Issues related to health care legislation; senior living services; implementation of CARES Act.
TRAVERE THERAPEUTICS via ALSTON & BIRD LLP
2020 · first_quarter · Q1
H.R. 1046, Medicare Price Negotiation and Competitive Licensing Act; FY 2020 Medicare and Medicaid proposals, including proposed International Pricing Index; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; H.R. 19, Lower Costs, More Cures Act of 2019; S. 2543, Prescription Drug Pricing Reduction Act of 2019; issues concerning diagnosis, treatment, patient care for rare kidney disease.
Issues related to the Orphan Drug Tax Credit; H.R. 2730/S. 1443, Credit for Caring Act of 2019; Coronavirus Aid, Relief, and Economic Security (CARES) Act and provisions regarding net operating loss (NOL).
NOVO NORDISK INC. via ALSTON & BIRD LLP
2020 · first_quarter · 1T
H.R. 1530/S. 595 Treat and Reduce Obesity Act; Medicare Diabetes Prevention Program; Issues related to Medicare Part D; Issues related to International Pricing Index (IPI)/reference pricing in Medicare; H.R. 107 - related to maximum Medicaid rebates; Medicare Part D Rebate Rule; H.R.3 Lower Drug Costs Now Act of 2019; H.R. 19, Lower Costs, More Cures Act of 2019; S. 2543, Prescription Drug Pricing Reduction Act of 2019; H.R. 4906/S. 2199, Insulin Price Reduction Act.
General diabetes prevention; medication affordability and access; S. 1948/H.R. 3709, Chronic Disease Management Act; issues related to high deductible health plan pre-deductible coverage of treatments and services for chronic diseases; Medication affordability and access.
MARYLAND+COALITION via ALSTON & BIRD LLP
2020 · first_quarter · Q1
Issues related to Medicare Advantage benchmarking and the Maryland All-Payer Demonstration.
Issues related to Medicare Advantage benchmarking and the Maryland All-Payer Demonstration.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2020 · first_quarter · Q1
Issues related to FDA regulation of tobacco products.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN COLLEGE OF GASTROENTEROLOGY via ALSTON & BIRD LLP
2020 · first_quarter · Q1
The Patient Protection and Affordable Care Act, Pub. L. 111-148, Section 4104; Colon cancer screening policies in Medicare; Medicare physician quality incentives; Advancement of physician quality registries as they relate to Medicare physician payment reform; Transparency in valuation of medical procedures under Medicare; Issues related to the Medicare physician fee schedule and payment policies for GI services; Proposed changes to Stark Law on self-referral and anti-kickback statute; Public Law 114-10 - The Medicare Access and CHIP Reauthorization Act of 2015 - implementation of payment model and reporting requirements, impact on physicians and QCDRs; physician burden reduction under Medicare, in general; Pub. Law 115-123, Section 51003, regarding technical amendments to Pub. Law 114-10; H.R. 1570/S. 668, The Removing Barriers to Colorectal Cancer Screening Act of 2019; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; issues regarding telehealth expansion.
AMERICAN COLLEGE OF GASTROENTEROLOGY via ALSTON & BIRD LLP
2019 · fourth_quarter · 4A
The Safe Step Act, H.R. 2279; Surprise Billing Legislation, in general; Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1531; Protecting People From Surprise Medical Bills Act, H.R. 3502; No Surprises Act, H.R. 3630; Lower Health Care Costs Act, S.1895.
The Patient Protection and Affordable Care Act, Pub. L. 111-148, Section 4104; Colon cancer screening policies in Medicare; Medicare physician quality incentives; Advancement of physician quality registries as they relate to Medicare physician payment reform; Transparency in valuation of medical procedures under Medicare; Issues related to the Medicare physician fee schedule and payment policies for GI services; Proposed changes to Stark Law on self-referral and anti-kickback statute; Public Law 114-10 - The Medicare Access and CHIP Reauthorization Act of 2015 - implementation of payment model and reporting requirements, impact on physicians and QCDRs; physician burden reduction under Medicare, in general; Pub. Law 115-123, Section 51003, regarding technical amendments to Pub. Law 114-10; H.R. 1570/S. 668, The Removing Barriers to Colorectal Cancer Screening Act of 2019; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act.
MARYLAND+COALITION via ALSTON & BIRD LLP
2019 · fourth_quarter · Q4
Issues related to Medicare Advantage benchmarking and the Maryland All-Payer Demonstration.
Issues related to Medicare Advantage benchmarking and the Maryland All-Payer Demonstration.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TRAVERE THERAPEUTICS via ALSTON & BIRD LLP
2019 · fourth_quarter · Q4
H.R. 1046, Medicare Price Negotiation and Competitive Licensing Act; FY 2020 Medicare and Medicaid proposals, including proposed International Pricing Index; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; H.R. 19, Lower Costs, More Cures Act of 2019; S. 2543, Prescription Drug Pricing Reduction Act of 2019.
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act.
NOVO NORDISK INC. via ALSTON & BIRD LLP
2019 · fourth_quarter · Q4
General diabetes prevention; medication affordability and access; S. 1948/H.R. 3709, Chronic Disease Management Act; issues related to high deductible health plan pre-deductible coverage of treatments and services for chronic diseases.
H.R. 1530/S. 595 Treat and Reduce Obesity Act; Medicare Diabetes Prevention Program; Issues related to Medicare Part D; Issues related to International Pricing Index (IPI)/reference pricing in Medicare; H.R. 107 - related to maximum Medicaid rebates; Medicare Part D Rebate Rule; H.R.3 Lower Drug Costs Now Act of 2019; H.R. 19, Lower Costs, More Cures Act of 2019; S. 2543, Prescription Drug Pricing Reduction Act of 2019; H.R. 4906/S. 2199, Insulin Price Reduction Act.
AMERICAN COLLEGE OF GASTROENTEROLOGY via ALSTON & BIRD LLP
2019 · fourth_quarter · Q4
The Safe Step Act, H.R. 2279; Surprise Billing Legislation, in general; Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1531; Protecting People From Surprise Medical Bills Act, H.R. 3502; No Surprises Act, H.R. 3630; Lower Health Care Costs Act, S.1895.
The Patient Protection and Affordable Care Act, Pub. L. 111-148, Section 4104; Colon cancer screening policies in Medicare; Medicare physician quality incentives; Advancement of physician quality registries as they relate to Medicare physician payment reform; Transparency in valuation of medical procedures under Medicare; Issues related to the Medicare physician fee schedule and payment policies for GI services; Proposed changes to Stark Law on self-referral and anti-kickback statute; Public Law 114-10 - The Medicare Access and CHIP Reauthorization Act of 2015 - implementation of payment model and reporting requirements, impact on physicians and QCDRs; physician burden reduction under Medicare, in general; Pub. Law 115-123, Section 51003, regarding technical amendments to Pub. Law 114-10; H.R. 1570/S. 668, The Removing Barriers to Colorectal Cancer Screening Act of 2019; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act.
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2019 · fourth_quarter · Q4
Issues related to FDA regulation of tobacco products.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK INC. via ALSTON & BIRD LLP
2019 · third_quarter · 3A
Issues related to the scoring of Preventive Health Savings Act, H.R. 2584/S. 1361.
General diabetes prevention; medication affordability and access; S. 1948/H.R. 3709, Chronic Disease Management Act; issues related to high deductible health plan pre-deductible coverage of treatments and services for chronic diseases.
H.R. 1530/S. 595 Treat and Reduce Obesity Act; Medicare Diabetes Prevention Program; Issues related to Medicare Part D; Issues related to International Pricing Index (IPI)/reference pricing in Medicare; H.R. 107 - related to maximum Medicaid rebates; Medicare Part D Rebate Rule; H.R.3 Lower Drug Costs Now Act of 2019.
NOVO NORDISK INC. via ALSTON & BIRD LLP
2019 · second_quarter · 2A
General diabetes prevention; medication affordability and access; S. 1948/H.R. 3709, Chronic Disease Management Act; issues related to high deductible health plan pre-deductible coverage of treatments and services for chronic diseases.
Issues related to the scoring of Preventive Health Savings Act, H.R. 2584/S. 1361.
H.R. 1530/S. 595 Treat and Reduce Obesity Act; Medicare Diabetes Prevention Program; Issues related to Medicare Part D; Issues related to International Pricing Index (IPI)/reference pricing in Medicare; H.R. 107 - related to maximum Medicaid rebates; Medicare Part D Rebate Rule.
NOVO NORDISK INC. via ALSTON & BIRD LLP
2019 · first_quarter · 1A
H.R. 1530/S. 595 Treat and Reduce Obesity Act; Medicare Diabetes Prevention Program; Issues related to Medicare Part D; Issues related to International Pricing Index (IPI)/reference pricing in Medicare; H.R. 107 - related to maximum Medicaid rebates; Medicare Part D Rebate Rule.
General diabetes prevention; medication affordability and access; issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases.
Issues related to CBO scoring of preventive health services.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TRAVERE THERAPEUTICS via ALSTON & BIRD LLP
2019 · third_quarter · Q3
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act; Newborn Screening legislation in general; Newborn Screening Saves Lives Reauthorization Act of 2019, H.R. 2507; Lower Health Care Costs Act, S. 1895; H.R. 4144, Ending the Diagnostic Odyssey Act of 2019.
Medical research, NIH funding, related appropriations issues; Senate Labor HHS Appropriations Act.
Issues related to the Orphan Drug Tax Credit; H.R. 2730/S. 1443, Credit for Caring Act of 2019.
NOVO NORDISK INC. via ALSTON & BIRD LLP
2019 · third_quarter · Q3
General diabetes prevention; medication affordability and access; S. 1948/H.R. 3709, Chronic Disease Management Act; issues related to high deductible health plan pre-deductible coverage of treatments and services for chronic diseases.
Issues related to the scoring of Preventive Health Savings Act, H.R. 2584/S. 1361.
H.R. 1530/S. 595 Treat and Reduce Obesity Act; Medicare Diabetes Prevention Program; Issues related to Medicare Part D; Issues related to International Pricing Index (IPI)/reference pricing in Medicare; H.R. 107 - related to maximum Medicaid rebates; Medicare Part D Rebate Rule; H.R.3 Lower Drug Costs Now Act of 2019.
LEADINGAGE, INC. via ALSTON & BIRD LLP
2019 · third_quarter · 3T
Issues related to LTSS financing and Medicaid BRCA; issues related to CNA training lock out.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MARYLAND+COALITION via ALSTON & BIRD LLP
2019 · third_quarter · Q3
Issues related to Medicare Advantage benchmarking and the Maryland All-Payer Demonstration.
Issues related to Medicare Advantage benchmarking and the Maryland All-Payer Demonstration.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2019 · third_quarter · Q3
Issues related to FDA regulation of tobacco products.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN COLLEGE OF GASTROENTEROLOGY via ALSTON & BIRD LLP
2019 · third_quarter · Q3
The Safe Step Act, H.R. 2279; Surprise Billing Legislation, in general; Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1531; Protecting People From Surprise Medical Bills Act, H.R. 3502; No Surprises Act, H.R. 3630; Lower Health Care Costs Act, S.1895.
The Patient Protection and Affordable Care Act, Pub. L. 111-148, Section 4104; Colon cancer screening policies in Medicare; Medicare physician quality incentives; Advancement of physician quality registries as they relate to Medicare physician payment reform; Transparency in valuation of medical procedures under Medicare; Issues related to the Medicare physician fee schedule and payment policies for GI services; Proposed changes to Stark Law on self-referral and anti-kickback statute; Public Law 114-10 - The Medicare Access and CHIP Reauthorization Act of 2015 - implementation of payment model and reporting requirements, impact on physicians and QCDRs; physician burden reduction under Medicare, in general; Pub. Law 115-123, Section 51003, regarding technical amendments to Pub. Law 114-10; H.R. 1570/S. 668, The Removing Barriers to Colorectal Cancer Screening Act of 2019.
MARYLAND+COALITION via ALSTON & BIRD LLP
2019 · second_quarter · Q2
Issues related to Medicare Advantage benchmarking and the Maryland All-Payer Demonstration.
Issues related to Medicare Advantage benchmarking and the Maryland All-Payer Demonstration.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TRAVERE THERAPEUTICS via ALSTON & BIRD LLP
2019 · second_quarter · Q2
Medical research, NIH funding, related appropriations issues.
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019.
NOVO NORDISK INC. via ALSTON & BIRD LLP
2019 · second_quarter · Q2
General diabetes prevention; medication affordability and access; S. 1948/H.R. 3709, Chronic Disease Management Act; issues related to high deductible health plan pre-deductible coverage of treatments and services for chronic diseases.
H.R. 1530/S. 595 Treat and Reduce Obesity Act; Medicare Diabetes Prevention Program; Issues related to Medicare Part D; Issues related to International Pricing Index (IPI)/reference pricing in Medicare; H.R. 107 - related to maximum Medicaid rebates; Medicare Part D Rebate Rule.
Issues related to the scoring of Preventive Health Savings Act, H.R. 2584/S. 1361.
AMERICAN COLLEGE OF GASTROENTEROLOGY via ALSTON & BIRD LLP
2019 · second_quarter · Q2
The Safe Step Act, H.R. 2279; Surprise Billing Legislation, in general; Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1531; Protecting People From Surprise Medical Bills Act, H.R. 3502; No Surprises Act, H.R. 3630; Lower Health Care Costs Act, S.1895.
The Patient Protection and Affordable Care Act, Pub. L. 111-148, Section 4104; Colon cancer screening policies in Medicare; Medicare physician quality incentives; Advancement of physician quality registries as they relate to Medicare physician payment reform; Transparency in valuation of medical procedures under Medicare; Issues related to the Medicare physician fee schedule and payment policies for GI services; Proposed changes to Stark Law on self-referral and anti-kickback statute; Public Law 114-10 - The Medicare Access and CHIP Reauthorization Act of 2015 - implementation of payment model and reporting requirements, impact on physicians and QCDRs; physician burden reduction under Medicare, in general; Pub. Law 115-123, Section 51003, regarding technical amendments to Pub. Law 114-10; H.R. 1570/S. 668, The Removing Barriers to Colorectal Cancer Screening Act of 2019.
LEADINGAGE, INC. via ALSTON & BIRD LLP
2019 · second_quarter · Q2
Issues related to LTSS financing and Medicaid BRCA; issues related to CNA training lock out.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2019 · second_quarter · Q2
Issues related to FDA regulation of tobacco products.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
TRAVERE THERAPEUTICS via ALSTON & BIRD LLP
2019 · first_quarter · Q1
H.R. 1046, Medicare Price Negotiation and Competitive Licensing Act; FY 2020 Medicare and Medicaid proposals, including proposed International Pricing Index.
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act.
Issues related to the Orphan Drug Tax Credit.
PREMIER, INC. via ALSTON & BIRD LLP
2019 · first_quarter · Q1
Issues regarding group purchasing organizations and health care delivery reform.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, White House Office
NOVO NORDISK INC. via ALSTON & BIRD LLP
2019 · first_quarter · Q1
General diabetes prevention; medication affordability and access; issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases.
Issues related to CBO scoring of preventive health services.
H.R. 1530/S. 595 Treat and Reduce Obesity Act; Medicare Diabetes Prevention Program; Issues related to Medicare Part D; Issues related to International Pricing Index (IPI)/reference pricing in Medicare; H.R. 107 - related to maximum Medicaid rebates; Medicare Part D Rebate Rule.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LEADINGAGE, INC. via ALSTON & BIRD LLP
2019 · first_quarter · Q1
Issues related to LTSS financing and Medicaid BRCA; issues related to CNA training lock out.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MARYLAND+COALITION via ALSTON & BIRD LLP
2019 · first_quarter · Q1
Issues related to Medicare Advantage benchmarking and the Maryland All-Payer Demonstration.
Issues related to Medicare Advantage benchmarking and the Maryland All-Payer Demonstration.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GREATER NEW YORK HOSPITAL ASSOCIATION via ALSTON & BIRD LLP
2019 · first_quarter · Q1
Issues regarding group purchasing organizations and health care delivery reform.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, White House Office
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2019 · first_quarter · Q1
Issues related to FDA regulation of tobacco products.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN COLLEGE OF GASTROENTEROLOGY via ALSTON & BIRD LLP
2019 · first_quarter · Q1
The Patient Protection and Affordable Care Act, Pub. L. 111-148, Section 4104; Colon cancer screening policies in Medicare; Medicare physician quality incentives; Advancement of physician quality registries as they relate to Medicare physician payment reform; Transparency in valuation of medical procedures under Medicare; Issues related to the Medicare physician fee schedule and payment policies for GI services; Proposed changes to Stark Law on self-referral and anti-kickback statute; Public Law 114-10 - The Medicare Access and CHIP Reauthorization Act of 2015 - implementation of payment model and reporting requirements, impact on physicians and QCDRs; physician burden reduction under Medicare, in general; Pub. Law 115-123, Section 51003, regarding technical amendments to Pub. Law 114-10; H.R. 1570/S. 668, The Removing Barriers to Colorectal Cancer Screening Act of 2019.
Restoring Patients Voice Act (115th Cong.)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NOVO NORDISK INC. via ALSTON & BIRD LLP
2018 · fourth_quarter · 4A
General diabetes prevention; medication affordability and access; H.R. 4978/S. 2410, Chronic Disease Management Act of 2018; National Obesity Care Week.
Medicare Diabetes Prevention Program; diabetes self-management education; H.R. 3124/S. 1299/Preventing Diabetes in Medicare Act; H.R. 1953/S. 830 Treat and Reduce Obesity Act; Issues related to Medicare Part D included in Section 53116 of H.R. 1892 (Pub. L. 115-123), Bipartisan Budget Act and H.R. 1625 (Pub. L. 115-141), Consolidated Appropriations Act; H.R. 849/S. 260 including coverage gap ("donut hole") access and averting catastrophic coverage Out of Pocket (OOP) "cliff"; Protecting Seniors' Access to Medicare Act of 2017 and S. 251 Protecting Medicare from Executive Action Act of 2017 (IPAB Repeal); H.R. 3921 HEALTHY KIDS Act (CHIP Reauthorization).
NOVO NORDISK INC. via ALSTON & BIRD LLP
2018 · third_quarter · 3A
Issues related to inbound investment in H.R.4311/S.2098 Foreign Investment Risk Review Modernization Act of 2017 (CFIUS Reform).
H.R.2953/S. 2164, Preventive Health Savings Act (CBO scoring of preventive health); National Diabetes Prevention Program and other CDC diabetes prevention activities in P.L. 115-96 (CR of FY18 Labor, Health and Human Services, and Education Appropriations), and FY19 Labor, Health and Human Services, and Education Appropriations.
Medicare Diabetes Prevention Program; diabetes self-management education; H.R. 3124/S. 1299/Preventing Diabetes in Medicare Act; H.R. 1953/S. 830 Treat and Reduce Obesity Act; Issues related to Medicare Part D included in Section 53116 of H.R. 1892 (Pub. L. 115-123), Bipartisan Budget Act and H.R. 1625 (Pub. L. 115-141), Consolidated Appropriations Act; H.R. 849/S. 260 including coverage gap ("donut hole") access and averting catastrophic coverage Out of Pocket (OOP) "cliff"; Protecting Seniors' Access to Medicare Act of 2017 and S. 251 Protecting Medicare from Executive Action Act of 2017 (IPAB Repeal); H.R. 3921 HEALTHY KIDS Act (CHIP Reauthorization).
NOVO NORDISK INC. via ALSTON & BIRD LLP
2018 · second_quarter · 2A
Medicare Diabetes Prevention Program; diabetes self-management education; H.R. 3124/S. 1299/Preventing Diabetes in Medicare Act; H.R. 1953/S. 830 Treat and Reduce Obesity Act; Issues related to Medicare Part D included in Section 53116 of H.R. 1892 (Pub. L. 115-123), Bipartisan Budget Act and H.R. 1625 (Pub. L. 115-141), Consolidated Appropriations Act; H.R. 849/S. 260 Protecting Seniors' Access to Medicare Act of 2017 and S. 251 Protecting Medicare from Executive Action Act of 2017 (IPAB Repeal); H.R. 3921 HEALTHY KIDS Act (CHIP Reauthorization).
Issues related to inbound investment in H.R.4311/S.2098 Foreign Investment Risk Review Modernization Act of 2017 (CFIUS Reform).
MARYLAND+COALITION via ALSTON & BIRD LLP
2018 · fourth_quarter · Q4
Issues related to Medicare Advantage benchmarking and the Maryland All-Payer Demonstration.
Issues related to Medicare Advantage benchmarking and the Maryland All-Payer Demonstration.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TRAVERE THERAPEUTICS via ALSTON & BIRD LLP
2018 · fourth_quarter · Q4
Rare disease patient care and screening and coverage issues in authorization and appropriations legislation; S. 1151/H.R. 2505, Credit for Caring Act; H.R. Res. 1154/S. Res. 690, Affirming the importance of the Orphan Drug Act, et al.
Tax legislation relating to the Orphan Drug Tax Credit, development, and rare disease patient issues; implementation of HR 1, the Tax Cuts and Jobs Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK INC. via ALSTON & BIRD LLP
2018 · fourth_quarter · Q4
General diabetes prevention; medication affordability and access; H.R. 4978/S. 2410, Chronic Disease Management Act of 2018; National Obesity Care Week.
Issues related to inbound investment in H.R. 4311/S. 2098 Foreign Investment Risk Review Modernization Act of 2017 (CFIUS Reform).
H.R. 2953/S. 2164, Preventive Health Savings Act (CBO scoring of preventive health); National Diabetes Prevention Program and other CDC diabetes prevention activities in P.L. 115-96 (CR of FY18 Labor, Health and Human Services, and Education Appropriations), and FY19 Labor, Health and Human Services, and Education Appropriations.
PREMIER, INC. via ALSTON & BIRD LLP
2018 · fourth_quarter · Q4
Issues regarding group purchasing organizations and health care delivery reform.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, White House Office
LEADINGAGE, INC. via ALSTON & BIRD LLP
2018 · fourth_quarter · Q4
Issues related to LTSS financing and Medicaid BRCA; issues related to CNA training lock out.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues pertaining to the use, regulation and development of Health Information Exchanges.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Issues pertaining to the use, regulation and development of Health Information Exchanges
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act; Newborn Screening legislation in general; Newborn Screening Saves Lives Reauthorization Act of 2019, H.R. 2507; Lower Health Care Costs Act, S. 1895; H.R. 4144, Ending the Diagnostic Odyssey Act of 2019; H.R. 534, Aidan's Law (newborn screening for ALD); H.R. 5062, Advancing Access to Precision Medicine Act; Kidney disease diagnosis, prevention, and care; H.R. 4712, Fairness in Orphan Drug Exclusivity Act; Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues concerning rare disease patients; Executive Order regarding Advancing American Kidney Health; issues concerning diagnosis, treatment, patient care for rare kidney disease; support of telehealth policies for rare disease patients; H.R. 133, Consolidated Appropriations Act of 2021.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act; Newborn Screening legislation in general; Newborn Screening Saves Lives Reauthorization Act of 2019, H.R. 2507; Lower Health Care Costs Act, S. 1895; H.R. 4144, Ending the Diagnostic Odyssey Act of 2019; H.R. 534, Aidan's Law (newborn screening for ALD); H.R. 5062, Advancing Access to Precision Medicine Act; Kidney disease diagnosis, prevention, and care; H.R. 4712, Fairness in Orphan Drug Exclusivity Act; Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues concerning rare disease patients; Executive Order regarding Advancing American Kidney Health; issues concerning diagnosis, treatment, patient care for rare kidney disease; support of telehealth policies for rare disease patients.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
The Safe Step Act, H.R. 2279; Surprise Billing Legislation, in general; Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1531; Protecting People From Surprise Medical Bills Act, H.R. 3502; No Surprises Act, H.R. 3630; Lower Health Care Costs Act, S.1895; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers; H.R. 266/P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act - provisions related to Public Health and Social Services Emergency Fund to provide further relief to physician practices.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act; Newborn Screening legislation in general; Newborn Screening Saves Lives Reauthorization Act of 2019, H.R. 2507; Lower Health Care Costs Act, S. 1895; H.R. 4144, Ending the Diagnostic Odyssey Act of 2019; H.R. 534, Aidan's Law (newborn screening for ALD); H.R. 5062, Advancing Access to Precision Medicine Act; Kidney disease diagnosis, prevention, and care; H.R. 4712, Fairness in Orphan Drug Exclusivity Act; Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues concerning rare disease patients; Executive Order regarding Advancing American Kidney Health; issues concerning diagnosis, treatment, patient care, for rare kidney disease.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to the scoring of Preventive Health Savings Act, H.R. 2584/S. 1361.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
The Safe Step Act, H.R. 2279; Surprise Billing Legislation, in general; Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019, S. 1531; Protecting People From Surprise Medical Bills Act, H.R. 3502; No Surprises Act, H.R. 3630; Lower Health Care Costs Act, S.1895; COVID-19 regulatory changes in general; Coronavirus Preparedness and Response Supplemental Appropriations (CPRSA) Act, the Families First Coronavirus Response Act (FFCRA), and the Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues impacting GI patients, physicians and ambulatory surgery centers.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Medical research, NIH funding, related appropriations issues; Senate Labor HHS Appropriations Act; H.R. 1158, Consolidated Appropriations Act of 2020.
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act; Newborn Screening legislation in general; Newborn Screening Saves Lives Reauthorization Act of 2019, H.R. 2507; Lower Health Care Costs Act, S. 1895; H.R. 4144, Ending the Diagnostic Odyssey Act of 2019; H.R. 534, Aidan's Law (newborn screening for ALD); H.R. 5062, Advancing Access to Precision Medicine Act; Kidney disease diagnosis, prevention, and care; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
Issues related to the Orphan Drug Tax Credit; H.R. 2730/S. 1443, Credit for Caring Act of 2019.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to the scoring of Preventive Health Savings Act, H.R. 2584/S. 1361.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act.
H.R. 1046, Medicare Price Negotiation and Competitive Licensing Act; FY 2020 Medicare and Medicaid proposals, including proposed International Pricing Index.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act; Newborn Screening legislation in general; Newborn Screening Saves Lives Reauthorization Act of 2019, H.R. 2507; Lower Health Care Costs Act, S. 1895.
H.R. 1046, Medicare Price Negotiation and Competitive Licensing Act; FY 2020 Medicare and Medicaid proposals, including proposed International Pricing Index.
Issues related to the Orphan Drug Tax Credit; H.R. 2730/S. 1443, Credit for Caring Act of 2019.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act.
Medical research, NIH funding, related appropriations issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 2953/S. 2164, Preventive Health Savings Act (CBO scoring of preventive health); National Diabetes Prevention Program and other CDC diabetes prevention activities in P.L. 115-96 (CR of FY18 Labor, Health and Human Services, and Education Appropriations), and FY19 Labor, Health and Human Services, and Education Appropriations.
Issues related to inbound investment in H.R. 4311/S. 2098 Foreign Investment Risk Review Modernization Act of 2017 (CFIUS Reform).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General diabetes prevention; World Hemophilia Day; medication affordability and access; H.E.4978/S. 2410, Chronic Disease Management Act of 2018; Growth Awareness Week 2018.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General diabetes prevention; World Hemophilia Day; medication affordability and access; H.E.4978/S. 2410, Chronic Disease Management Act of 2018.
H.R.2953/S. 2164, Preventive Health Savings Act (CBO scoring of preventive health); National Diabetes Prevention Program and other CDC diabetes prevention activities in P.L. 115-96 (CR of FY18 Labor, Health and Human Services, and Education Appropriations).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Medicare Diabetes Prevention Program; diabetes self-management education; H.R. 3124/S. 1299/Preventing Diabetes in Medicare Act; H.R. 1953/S. 830 Treat and Reduce Obesity Act; Issues related to Medicare Part D included in Section 53116 of H.R. 1892 (Pub. L. 115-123), Bipartisan Budget Act and H.R. 1625 (Pub. L. 115-141), Consolidated Appropriations Act; H.R. 849/S. 260 including coverage gap ("donut hole") access and averting catastrophic coverage Out of Pocket (OOP) "cliff"; Protecting Seniors' Access to Medicare Act of 2017 and S. 251 Protecting Medicare from Executive Action Act of 2017 (IPAB Repeal); H.R. 3921 HEALTHY KIDS Act (CHIP Reauthorization).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE